last week flu report strong quarter
patient util growth consist model margin
weaker expect management opportunist hire rep
acceler invest train educ think make
sens overal view revenu opportun compani
whole unchang revenu growth like import
feel investor start pay attent ebit abmd
market cap soar share like pick mid
larg cap fund often put emphasi earn vs smaller
cap fund care revenu growth still feel
remain clean stori neutral rate base lofti
ntm revenu multipl seen outsiz reaction might
view insuffici beat biggest risk view mani
investor want revenu ebit beat quarter
occur valuat could pull bit quarter like
import stemi data aha novemb could
uptak japan continu impella revenu better
model better forecast ou bit softer
forecast though growth germani japan remain
stellar japan sale feel full year guidanc
remain conserv notabl management indic establish
earli presenc countri includ india
stemi enrol complet data aha could catalyst
surprisingli complet patient feasibl studi
ahead schedul compani dialogu fda
eye toward data public releas aha meet
chicago plan preview data expect
get closer meet
valuat maintain neutral rate risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani report world-wide impella revenu reflect
improv y/i impella revenu better
forecast impella patient util support
growth protect pci shock meanwhil ou impella
revenu bit shi forecast despit solid growth
germani japan overal seem driver impella momentum
gross margin vs last year y/i pressur attribut
product geograph mix well manufactur invest
intend support futur top-lin growth sg spend
higher model compani hire rep
think vs incur cost associ train program
overal ebit margin better y/i lower street
estim told ep boost excess tax
benefit relat stock-bas comp exclud benefit
quarter estim ep would closer vs
actualsbtig estimate varianceu impella sale trial impella sale revenu growth net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani estim non- exclud incom tax benefit relat stock option
maintain revenu forecast expens trend
higher expect trim ebit margin forecast
adj ep forecast includ
tax benefit importantli forecast benefit go forward thu
estim may directli compar street estim
rate neutral feel compani above-averag revenu
growth gross margin warrant premium multipl peer
share ntm revenu estim fewer near-term catalyst
move materi higher near-term think share risk-
reward roughli equal btig provid price target neutral-r
stock risk includ reimburs slippag product timelin chang
procedur patent litig futur devic data fda possibl
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom btig estim compani model tax benefit go-forward basi estim may directli compar consensu forecast newold changentm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg sg -- tax- amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
